The U.S. Department of Commerce has issued procedures for pharmaceutical manufacturers to apply for onshoring agreements that may qualify them for reduced Section 232 tariff rates on imported products and ingredients.
Key points
- Companies can apply for onshoring agreements to reduce Section 232 tariffs on pharmaceuticals and ingredients.
- Applications must be submitted within 30 days of the Federal Register publication.
- Agreement terms determine eligibility and the level of tariff adjustment.
- The Department of Commerce administers the onshoring agreement process.
- Only companies manufacturing pharmaceutical products are eligible to apply.
- The notice defines the procedures but not the final tariff rates or eligibility outcomes.
What Changed and Its Scope
This notice establishes the procedures for pharmaceutical manufacturers to apply for company-specific onshoring agreements with the U.S. Department of Commerce. These agreements are designed to support onshoring of pharmaceutical production and associated ingredient manufacturing within the United States.
Companies that enter into such agreements may become eligible for reduced Section 232 duty rates on imports of their pharmaceutical products and related ingredients. The scope of eligibility and the extent of tariff adjustments are defined by the terms of the individual agreement, as set out in the official notice.
Who Is Affected and What to Check
U.S.-based pharmaceutical manufacturers and importers of pharmaceutical products and ingredients are affected, particularly those seeking to reduce Section 232 tariffs under Proclamation 11020. The notice applies to companies that intend to onshore production and are seeking tariff adjustments through formal agreements.
Importers should verify whether their company qualifies for an onshoring agreement, review the application procedures, and ensure submission within 30 days of the Federal Register publication date. The full terms, including eligibility criteria and required documentation, are set out in the official notice and must be consulted directly.
FAQ
Who can apply for a company-specific onshoring agreement under this notice?
Pharmaceutical manufacturers in the United States that produce pharmaceutical products or their ingredients may apply. The notice specifies that eligibility is limited to companies engaged in pharmaceutical manufacturing and seeking to onshore production. The full criteria, including required documentation and compliance standards, are defined in the official notice and must be reviewed by applicants.
What is the deadline to submit an application for an onshoring agreement?
Companies must submit their applications within 30 days of the publication date in the Federal Register. The notice does not specify a calendar date for the deadline, but it is calculated from May 13, 2026, the published date. Importers and manufacturers should track this timeline closely and ensure all documentation is prepared and submitted before the 30-day window closes.
Official source: Commerce Department, Industry and Security Bureau — Procedures To Apply for Company-Specific Onshoring Agreements To Obtain Tariff Adjustments for Pharmaceuticals and Pharmaceutical Ingredients Under Proclamation 11020 (2026-05-13)
This is an informational summary based on the official government notice. It does not constitute legal advice. Importers and companies must consult the full notice at the official URL and seek guidance from qualified trade compliance professionals to ensure compliance with all requirements.
Leave a Reply